News
CMXHF
96.20
NaN%
--
Positive Report for CSL (CMXHF) from Jarden
TipRanks · 5h ago
Morgan Stanley Remains a Buy on CSL (CMXHF)
TipRanks · 1d ago
Bell Potter Keeps Their Hold Rating on CSL (CMXHF)
TipRanks · 1d ago
Analysts Offer Insights on Healthcare Companies: Pro Medicus Limited (OtherPMCUF) and CSL (OtherCMXHF)
TipRanks · 1d ago
Citi Keeps Their Hold Rating on CSL (CMXHF)
TipRanks · 1d ago
Haemonetics rises after supply deal with CSL
Seeking Alpha · 1d ago
Macquarie Sticks to Its Hold Rating for CSL (CMXHF)
TipRanks · 2d ago
CSL (CMXHF) Receives a Buy from UBS
TipRanks · 2d ago
CSL Marks FY26 as Reset Year Amid Impairments, Transformation Drive
TipRanks · 2d ago
CSL posts revenue growth but swings to loss ahead of 2026 AGM
TipRanks · 2d ago
CSL Confirms Lapse of 37,550 Conditional Rights Securities
TipRanks · 08/05 23:13
UBS Sticks to Its Buy Rating for CSL (CMXHF)
TipRanks · 07/31 13:36
Bell Potter Sticks to Their Hold Rating for CSL (CMXHF)
TipRanks · 07/31 00:05
Analysts Conflicted on These Healthcare Names: CSL (OtherCMXHF), Oneview Healthcare Chess Depository Interests repr 1 (OtherONVVF) and Polynovo (OtherCALZF)
TipRanks · 07/30 01:10
CSL (CMXHF) Gets a Hold from Jefferies
TipRanks · 07/29 12:46
Analysts Offer Insights on Healthcare Companies: CSL (OtherCMXHF) and Alkermes (ALKS)
TipRanks · 07/29 03:40
CSL to Test High-Yield Plasma Technology in New Immunoglobulin Trials
TipRanks · 07/29 00:04
Analysts Are Bullish on These Healthcare Stocks: Equillium (EQ), CSL (CMXHF)
TipRanks · 07/24 05:00
Ord Minnett Reaffirms Their Hold Rating on CSL (CMXHF)
TipRanks · 07/23 00:35
Analysts Have Conflicting Sentiments on These Healthcare Companies: Telix Pharmaceuticals (OtherTLPPF) and CSL (OtherCMXHF)
TipRanks · 07/22 23:40
More
Webull provides a variety of real-time CMXHF stock news. You can receive the latest news about CSL through multiple platforms. This information may help you make smarter investment decisions.
About CMXHF
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.